Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation

Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation

Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients, for which chemopreventive strategies are lacking. Recently, we developed a simple human cell-based system modeling a clinical prognostic liver signature (PLS) predicting liver disease progression and HCC risk. In a...

Full description

Bibliographic Details
Main Authors: Arora, G. (Author), Bandiera, S. (Author), Barrett, S.C (Author), Baumert, T.F (Author), Chung, R.T (Author), Crouchet, E. (Author), Del Zompo, F. (Author), Durand, S.C (Author), El Saghire, H. (Author), Felli, E. (Author), Fuchs, B.C (Author), Fujiwara, N. (Author), Ghoshal, S. (Author), Giannone, F. (Author), Hoshida, Y. (Author), Li, S. (Author), Lupberger, J. (Author), Oudot, M.A (Author), Pessaux, P. (Author), Pochet, N. (Author), Ponsolles, C. (Author), Qian, T. (Author), Rasha, F.A (Author), Schaeffer, E. (Author), Schuster, C. (Author), Slovic, N. (Author), Sojoodi, M. (Author), Tanabe, K.K (Author), Van Renne, N. (Author), Zhu, S. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
Fibrosis
Hepatology
Liver cancer
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items